Meeting
2015 Genitourinary Cancers Symposium
Targeting the PI3K/AKT/mTOR pathway with MLN0128 (mTORC1/2 inh) and MLN1117 (PI3K alpha inh) in bladder cancer: Rational for its testing in clinical trials.
Authors
Alejandro Martinez
University Hospital del Mar, IMIM, Barcelona, Spain
Alejandro Martinez , Anna Hernandez , Oriol Arpi , Silvia Menendez , Natalia Iarchouk , Elena Gavilan , Beatriz Bellosillo , Montserrat Arumí , Federico Rojo , Stephanie A. Mullane , Toni K. Choueiri , Ana Rovira , Joan Albanell , Rachael Brake , Joaquim Bellmunt
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session B: Prostate, Penile, Testicular, and Urethral Cancers, and Urothelial Carcinoma
Track
Urothelial Carcinoma,Prostate Cancer,Penile, Urethral, and Testicular Cancers
Sub Track
Urothelial Carcinoma
Citation
J Clin Oncol 33, 2015 (suppl 7; abstr 369)
DOI
10.1200/jco.2015.33.7_suppl.369
Abstract #
369
Poster Bd #
H6
Abstract Disclosures
Similar Posters
Poster
2018 Genitourinary Cancers Symposium
Role of mTORC2 and nitric oxide in bladder cancer invasion.
First Author: Divya Sahu
Poster
2015 Genitourinary Cancers Symposium
Safety and efficacy of temsirolimus as second-line treatment for patients with recurrent bladder cancer.
First Author: Nadine Houede
Poster
2024 ASCO Genitourinary Cancers Symposium
MAPK pathway alterations as a targetable vulnerability in bladder cancer.
First Author: Vincent D'Andrea
Poster
2023 ASCO Annual Meeting
A phase II trial with copanlisib plus avelumab as maintenance therapy for metastatic bladder cancer after platinum-based chemotherapy.
First Author: Hizra Farrukh